416 G.A. Cabral and A. Staab
Cabral GA, Lockmuller JC, Mishkin EM (1986a) Delta-9-tetrahydrocannabinol decreases
alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse.
Proc Soc Exp Biol Med 181:305–311
Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, Munson AE (1986b) Effect
of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the
guinea pig. Proc Soc Exp Biol Med 182:181–186
Cabral GA, McNerney PJ, Mishkin EM (1987a) Interaction of delta-9-tetrahydrocannabinol
with rat B103 neuroblastoma cells. Arch Toxicol 60:438–449
Cabral GA, McNerney PJ, Mishkin EM (1987b) Delta-9-tetrahydrocannabinol inhibits the
splenocyte proliferative response to herpes simplex virus type 2. Immunopharmacol
Immunotoxicol 9:361–370
Caiaffa WT, Vlahov D, Graham NM, Astemborski J, Solomon L, Nelson KE, Munoz A (1994)
Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase
risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection
drug users. Am J Respir Crit Care Med 150:1493–1498
Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiegue
S, Mondière P, Penarier G, Le Fur GL, Defrance T, Casellas P (1998) Modulation and
functional involvement of CB2 peripheral cannabinoid receptors during B-cell differ-
entiation. Blood 92:3605–3615
Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA (2002) Differential expression
of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in
relation to cell activation. Int Immunopharmacol 2:69–82
Carrasco L, Smith AE (1976) Sodium ions and the shut-off of host cell protein synthesis by
picornaviruses. Nature 264:807–809
Coates RA, Farewell VT, Raboud J, Read SE, MacFadden DK, Calzavara LM, Johnson JK,
Shepherd FA, Fanning MM (1990) Cofactors of progression to acquired immunodefi-
ciency syndrome in a cohort of male sexual contacts of men with human immunodefi-
ciency virus disease. Am J Epidemiol 132:717–722
Coffey RG, Yamamoto Y, Snella E, Pross S (1996) Tetrahydrocannabinol inhibition of
macrophage nitric oxide production. Biochem Pharmacol 52:743–751
Cohen S (1976) The 94-day cannabis study. Ann N Y Acad Sci 282:211–220
Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996) Cannabinoid inhibition of
adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in
the murine T-cell line, EL4.IL-2. J Biol Chem 271:13175–13183
Crosby R, Diclemente RJ, Wingood GM, Harrington K, Davies SL, Hook EW, III, Oh MK
(2002) Predictors of infection with Trichomonas vaginalis: a prospective study of low
income African-American adolescent females. Sex Transm Infect 78:360–364
Croxford JL, Miller SD (2003) Immunoregulation of a viral model of multiple sclerosis using
the synthetic cannabinoid R+WIN55,212. J Clin Invest 111:1231–1240
DaakaY,KleinTW,FriedmanH(1995)ExpressionofcannabinoidreceptormRNAinmurine
and human leukocytes. Adv Exp Med Biol 373:91–96
Daaka Y, Friedman H, Klein TW (1996) Cannabinoid receptor proteins are increased in
Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 276:776–783
Daaka Y, Zhu W, Friedman H, Klein TW (1997) Induction of interleukin-2 receptor alpha
gene by delta-9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1
cannabinoid receptor. DNA Cell Biol 16:301–309
DePetrocellisL,MelckD,PalmisanoA,BisognoT,LaezzaC,BifulcoM,DiMarzoV
(1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell
proliferation. Proc Natl Acad Sci U S A 95:8375–8380
Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995) Cannabinoids enhance human
B-cell growth at low nanomolar concentrations. FEBS Lett 369:177–182
Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, Casellas P (1998)
The endogenous cannabinoid anandamide is a lipid messenger activating cell growth
via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett
425:419–425